24 results about "Suprachoroidal space" patented technology

Provided herein are pharmaceutical compositions for administration to a suprachoroidal space of an eye of a subject. The pharmaceutical compositions can include a recombinant adeno-associated virus (AAV) encoding a transgene. Also provided herein are methods for treating or preventing a disease in a subject by administering a therapeutically effective amount of the pharmaceutical compositions to the subject in need.

The invention relates to an injector adapter, an injection assembly and a using method. The injector adapter comprises a connecting piece, and a cavity is formed in the connecting piece; the guide pipe penetrates through the connecting piece and penetrates through the cavity, and the pipe wall, located in the cavity, of the guide pipe is provided with a penetrating channel; the elastic sheath is located in the cavity, the elastic sheath is arranged outside the catheter in a sleeving mode, a potential gap cavity is formed between the elastic sheath and the catheter, and the potential gap cavity is in fluid communication with the catheter through the penetrating channel. The injector adapter can be used in cooperation with an existing injector, so that an operator can more visually judge whether a needle head penetrates through the sclera to reach the suprachoroidal space or not so as to guide the operator to conduct medicine injection, and the injection convenience of the operator is remarkably improved.

The present disclosure provides methods for administering formulations to the suprachoroidal space of the eye to achieve targeted drug delivery to a desired site of action within the eye. The methods include using a pushing formulation that includes a material such as a gel that expands due to physiochemical cues; or using an electric field to affect the movement of a formulation within the suprachoroidal space; or a combination of a pushing formulation with an electric field.

The invention discloses a device and method for medicine injection of a suprachoroidal space, and relates to the technical field of medical instruments.The device for medicine injection of the suprachoroidal space comprises an injector shell; the injection cylinder is arranged in the injector shell in a penetrating mode, a needle head is fixedly arranged at the end, located in the injector shell, of the injection cylinder, and an injection piston is arranged at the other end of the injection cylinder in a penetrating mode. The tail end of the needle head can penetrate through the end, away from the injection piston, of the injector shell, and a pressure measuring device is arranged on the needle head. The linkage device can be switched to fix the injector shell and the injection cylinder or fix the injection cylinder and the injection piston; and the signal conversion module is in signal connection with the pressure measuring device and the linkage device, and can control the switching action of the linkage device according to the pressure signal at the needle head measured by the pressure measuring device. According to the device and the method for suprachoroidal cavity medicine injection, the suprachoroidal cavity part can be accurately positioned.

An ocular access instrument (20) includes an attachment assembly (32) configured to engage a sclera of an eye, and an actuator assembly (34) configured to bear against the sclera. When the attachment assembly engages the sclera, movement of the actuator assembly inwardly against the eye displaces the choroid from the sclera, thereby creating an enlarged suprachoroidal space. The ocular access instrument may also include a needle guide (40) configured to receive the needle and guide the needle into the enlarged suprachoroidal space.

This invention discloses an implantable stent for aqueous humor drainage in glaucoma, belonging to the field of ophthalmic implantable medical devices. The stent comprises a flexible tubular body, a passive pressure regulating valve, a pressure response module, an anchoring structure, a variable-diameter main drainage channel, a porous diffuse diversion structure at the tail, and a surface functionalized layer. The inflow end is placed in the anterior chamber or anterior chamber angle, and the outflow end is placed in the suprachoroidal space. When the pressure difference between the inflow and outflow ends reaches a preset threshold, the pressure valve opens, allowing aqueous humor to be uniformly introduced into the suprachoroidal space through the main channel and the porous diversion structure; when the pressure difference is below the threshold, the valve closes, limiting excessive drainage. The anchoring structure fixes the stent's position and prevents displacement. This invention achieves effective aqueous humor drainage while reducing the risk of excessive drainage, and improves the stent's implantation stability, drainage uniformity, and long-term follow-up evaluation capabilities.

A triamcinolone acetonide pharmaceutical composition and a preparation method therefor. The pharmaceutical composition contains the following ingredients: (i) a triamcinolone acetonide active ingredient, (ii) hyaluronic acid or a salt thereof. (iii) a buffering agent; and (iv) a tonicity adjustment agent. The pharmaceutical composition has a suitable viscosity, osmotic pressure and particle size range and is easily injected, especially administrated by means of a suprachoroidal space injection.

The invention provides a suprachoroidal implant system which comprises a suprachoroidal implant and a conveyor, the suprachoroidal implant is of a porous structure and is used for being implanted into a suprachoroidal cavity, and aqueous humor is discharged from a gap between the suprachoroidal cavity and the sclera to reduce intraocular pressure; the conveyor is used for implanting a suprachoroidal cavity implant into a suprachoroidal cavity, the conveyor comprises a shell, a sheath tube assembly, an ejection piece and a pushing assembly, and the shell forms a handle part of the conveyor; the sheathing canal assembly is detachably arranged at the head end of the handle part and can store a suprachoroidal space implant; the ejection piece is fixed in the handle part along the longitudinal direction of the handle part; the ejection piece is at least partially arranged in the guide sheath tube in a penetrating manner and can act on the suprachoroidal implant; the pushing assembly is at least partially exposed out of the handle part and can act on the sheathing canal assembly to guide the guiding sheathing canal to move in the longitudinal direction of the handle part, so that the ejection piece can push the suprachoroidal cavity implant out of the guiding sheathing canal and implant the suprachoroidal cavity implant into the suprachoroidal cavity.

Methods and devices are provided for targeted non-surgical administration of a drug formulation to the suprachoroidal space (SCS) of the eye of a human subject for the treatment of a posterior ocular disorder or a choroidal malady. In one embodiment, the method comprises inserting a hollow microneedle into the eye at an insertion site and infusing a drug formulation through the inserted microneedle and into the suprachoroidal space of the eye, wherein the infused drug formulation flows within the suprachoroidal space away from the insertion site during the infusion. In one embodiment, the fluid drug formulation comprises drug nanoparticles or microparticles.

An ocular implant system is described herein in which an implant (200) is deployed in the posterior space of an eye - e.g., the suprachoroidal space or the subconjunctival space or the intrascleral space - through an access in the anterior chamber (160) for reducing intraocular pressure in the eye. The shunt device (200) is implanted using an implantation device that includes a hollow shaft (330) mounted on a fixed shaft (320). The shunt device (200) is located in the distal end of the hollow shaft (330) and adjacent to the distal end of the fixed shaft (320) at a location behind the distal end of the hollow shaft. Once the distal end of the hollow shaft (330) and the shunt device (200) are at the desired depth within the posterior space, the hollow shaft is withdrawn over the fixed shaft through the access in the anterior chamber (160) towards the proximal end of the fixed shaft, leaving the shunt device in the posterior space.

A pre-filled syringe for injecting a pharmaceutical composition into an eye, comprising: a syringe barrel (1) having a proximal end and a distal end; a floating seal member (3) located within the syringe barrel (1); a needle hub located at the proximal end of the floating seal member (3), the floating seal member (3) and the needle hub being elastically engaged with each other; the pharmaceutical composition contained in a chamber (7) formed by the needle hub, the floating seal member (3) and the distal end of the syringe barrel (1); and a needle (6) for intraocular puncture, the needle (6) a needle (6) including (i) a needle proximal end engaged with a needle hub, (ii) a needle distal end, (iii) a needle distal end opening (6a), (iv) a needle body opening (6b) located between the needle proximal end and the needle distal end, the needle body opening (6b) being located at a proximal end of the needle distal end opening (6a), and (v) a needle body passage connecting the needle distal end opening (6a) and the needle body opening (6b), wherein the needle hub is configured to advance the needle distally toward and / or through the floating seal member.

A stent implant for treating glaucoma by intraocular fluid drainage from the anterior chamber, for example into the suprachoroidal space. The stent implant is designed to change in shape after being inserted into the eye, during which change the width and / or thickness or the flow cross-section is increased by for example 20%, in another example more than 200%, and in a further example by more than 400%, at least one point of the stent implant. In the case of intraocular fluid drainage from the anterior chamber into the suprachoroidal space, a cyclodialysis cleft which may open can be largely or completely closed. With appropriate adjustments, the stent implant can also be applied in trabecular, uveoscleral, uveolymphatic and subconjunctival applications for intraocular fluid drainage from the anterior chamber. The implant can even be used for direct intraocular fluid discharge from the anterior chamber onto the surface of the eye.

Conventional ways of reducing pressure in the eye have inherent drawbacks and one such way to reduce these drawbacks is to provide an ocular drainage implant including a pliable plate which is so sized and shaped as to enable it to be positioned on a sclera surface or a sub-scleral space of an eye comprising a first exterior face and a second exterior face, with a plurality of apertures extending between the first and second faces, and a fluid drainage tube retaining structure; and a valve-less fluid drainage tube connected to the retaining structure and providing the implant with a longitudinal axis, the valve-less fluid drainage tube being adapted to drain fluid from an anterior chamber of the eye to the subconjunctival or the suprachoroidal space, wherein the retaining structure extends substantially across an entire dimension of the plate.

This disclosure generally relates to the field of ophthalmic therapies, and more particularly to the treatment of various eye diseases and conditions by the non-surgical administration into a subject's eye of a pharmacological composition described herein containing a plasma kallikrein inhibitor. Avoralstat is included among the plasma kallikrein inhibitors. The compositions and methods include the administration of a plasma kallikrein inhibitor into the suprachoroidal space (SCS) of the eye.

The disclosure relates to ophthalmic implants, specifically a flexible, self-expanding spacer device deployable in subconjunctival, sub-Tenon's, or suprachoroidal spaces to manage intraocular fluids. The device addresses limitations of fixed-resistance drainage and fibrosis-related failure in glaucoma surgery by maintaining a controlled three-dimensional reservoir (bleb space) for aqueous humor outflow while minimizing tissue trauma. In one aspect, a shape-memory body transitions from a compressed, delivery-compatible state to an expanded configuration defining a convex internal volume, optionally with collapse-resistant reinforcements and tissue-engaging elements for atraumatic stabilization. Preferred embodiments include anterior relief geometry to avoid corneal contact and posterior flow-directing features to promote posterior bleb formation and uniform pressure control. A delivery member with a reduced-profile, tapered piercing tip and optional bent shaft enables minimally invasive ab externo implantation and controlled, coaxial deployment. Advantages include streamlined single-step delivery, stable long-term bleb architecture, reduced hypotony and fibrotic encapsulation, and compatibility with trabeculectomy and shunt-based outflow.

This invention relates to the field of biotechnology and discloses a method for screening drugs capable of preventing and / or treating posterior segment diseases of the eye. The method includes: first, decompressing the anterior chamber of an experimental animal; then, pre-establishing a "perforation-closure" channel in the sclera of the experimental animal; next, injecting the drug to be screened into the suprachoroidal space of the experimental animal through the "perforation-closure" channel in the sclera; and finally, evaluating the effectiveness of the drug in preventing and / or treating posterior segment diseases based on changes in the eye condition of the experimental animal. This invention reduces the incidence of ocular surface inflammation and improves safety by lowering intraocular pressure and creating a pre-closed scleral incision to prevent backflow of the injected AAV vector; it also provides a broader expression range and longer duration of action. Studies have shown that injecting shRNA targeting the TGF-β2 gene using the method of this invention inhibits myopia progression in a guinea pig model. The method provided by this invention is beneficial for screening gene therapy drugs related to posterior segment diseases.

The disclosure relates to ophthalmic implants, specifically a flexible, self-expanding spacer device deployable in subconjunctival, sub-Tenon's, or suprachoroidal spaces to manage intraocular fluids. The device addresses limitations of fixed-resistance drainage and fibrosis-related failure in glaucoma surgery by maintaining a controlled three-dimensional reservoir (bleb space) for aqueous humor outflow while minimizing tissue trauma. In one aspect, a shape-memory body transitions from a compressed, delivery-compatible state to an expanded configuration defining a convex internal volume, optionally with collapse-resistant reinforcements and tissue-engaging elements for atraumatic stabilization. Preferred embodiments include anterior relief geometry to avoid corneal contact and posterior flow-directing features to promote posterior bleb formation and uniform pressure control. A delivery member with a reduced-profile, tapered piercing tip and optional bent shaft enables minimally invasive ab externo implantation and controlled, coaxial deployment. Advantages include streamlined single-step delivery, stable long-term bleb architecture, reduced hypotony and fibrotic encapsulation, and compatibility with trabeculectomy and shunt-based outflow.

Ocular implants, kits and methods are disclosed. In one arrangement, an implant comprises a frame deployable in the suprachoroidal space of an eye and configured to resiliently adopt an arched elongate shape to promote drainage of aqueous humor through the suprachoroidal space when the frame is deployed in the suprachoroidal space. Relative to an axis of elongation of the elongate shape: the frame has a first axial end and a second axial end; and the arched elongate shape defines a channel. The channel has a first axial opening at the first axial end of the frame, a second axial opening at the second axial end of the frame, and a longitudinal opening extending continuously from the first axial end to the second axial end.

This disclosure is generally in the field of ophthalmic therapies, and more particularly to the treatment of various ocular diseases and conditions by non-surgical administration to the eye of a subject of a drug composition described herein containing a plasma kallikrein inhibitor. Plasma kallikrein inhibitors include avoralstat. The compositions and methods include delivery of a plasma kallikrein inhibitor to the suprachoroidal space (SCS) of the eye.

Minimally invasive, implantable ophthalmic drainage devices and systems for delivering the drainage devices are disclosed. The disclosed drainage devices may allow more stable implantation in the suprachoroidal space of an eye and control of fluid drainage from the eye for treating glaucoma. The disclosed delivery systems may improve control and reduce difficulty of device implantation.

The application discloses a construction method of a choroid melanin in-situ tumor animal model, and belongs to the technical field of biological medicine. The construction method comprises the following steps: providing tumor cells, wherein the tumor cells are mouse melanoma B16 cells; mixing luciferase-labeled tumor cells and biological gold medal matrix glue at 0-4 DEG C, and then injecting the mixture into the choroid layer through the suprachoroidal space of a mouse, so that the choroid melanin in-situ tumor animal model is obtained. The biological gold medal matrix glue is used as a carrier, the adhesion of the matrix glue and the cells is strong, and the cells can be uniformly dispersed in the matrix glue, so that the cells can be uniformly dispersed in the matrix glue. The matrix glue can be gelled in 1-3 minutes at room temperature, and can be rapidly solidified at 37 DEG C, so that the cells can be fixed in the choroid layer, and the real anatomical site of human choroid melanoma occurrence can be simulated. In addition, the matrix glue can provide a good nutrient environment for tumor growth, so that a single solid tumor can be formed by a tumor cell line in a short time.

To provide an improved apparatus for delivering medicament to a suprachoroidal space of an eye.SOLUTION: According to one aspect of the disclosure, an apparatus for manipulating a sclera to facilitate delivery of a medicament to a suprachoroidal space of an eye may include a needle with a sharp distalmost tip, a needle hub connected to a proximal end of the needle, a housing surrounding the needle hub and extending from a proximal end of the needle hub, and an adaptor surrounding a portion of the needle.SELECTED DRAWING: Figure 2

Provided herein are pharmaceutical compositions for administration to a suprachoroidal space of an eye of a subject. The pharmaceutical compositions can include a recombinant adeno-associated virus (AAV) encoding a transgene. Also provided herein are methods for treating or preventing a disease in a subject by administering a therapeutically effective amount of the pharmaceutical compositions to the subject in need.

The present invention discloses an ocular implant, comprising an implant body, wherein the implant body is in the shape of a strip, and the outer contour of the upper surface thereof is in the shape of a convex arch or semi-arch, for contacting the sclera, and the lower surface of the implant body is in the shape of a plane, for contacting the choroid; a longitudinal drainage groove is provided on the upper surface of the implant body along the front-to-back direction of the implant body. The implant body as a whole is in the structure of being gradually thinner at the front and back ends and thicker in the middle, or gradually thinner at the back end and thicker in the middle to the front end, so that it can smoothly enter the suprachoroidal space, expand the originally narrow suprachoroidal space, and increase the outflow of aqueous humor from the suprachoroidal space by means of the longitudinal drainage groove, thus having a good drainage effect, not prone to clogging, and playing a role in reducing intraocular pressure. The lower surface of the implant body is in the shape of a plane, and the area of ​​contact with the choroid is larger, which is conducive to stable attachment to the choroid, reducing the risk of displacement to the anterior chamber and choroid, avoiding exposure to the anterior chamber and touching the cornea, and minimizing the risk of corneal endothelial cell loss.